Efficacy and safety of nemolizumab in paediatric atopic dermatitis: A 24‐week real‐world case series

Documenti analoghi

• Real‐world experience of switching from tralokinumab to lebrikizumab in atopic dermatitis
  di: Teppei Hagino, et al.
  Pubblicazione: (2025)
• Real world experience of switching from tralokinumab to lebrikizumab: Author's reply
  di: Teppei Hagino, et al.
  Pubblicazione: (2025)
• Efficacy and safety of lebrikizumab in atopic dermatitis over 24 weeks: An analysis from the BIOREP registry
  di: Filip Rob, et al.
  Pubblicazione: (2025)
• Primary localized cutaneous amyloidosis associated with atopic dermatitis treated successfully with nemolizumab
  di: Takeshi Fukumoto, et al.
  Pubblicazione: (2024)
• Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study
  di: Matthias Augustin, et al.
  Pubblicazione: (2025)